Lantheus Q3 Revenue Rises 1.5%; Adjusted EPS Reaches $1.68
Lantheus reported Q3 2026 revenue of $389.9M, up 1.5% YoY, with adjusted EPS at $1.68. The company received FDA approvals for TAUKLARIFY and BRAVNETSA. Lantheus suspended 2026 guidance due to its pending merger with Curium at $102.50 per share plus potential CVRs.
How this was made
The 30-second read
Why it matters
The earnings beat and regulatory clearances provide short‑term upside, while the merger adds a longer‑term catalyst. Investors may trade the spread between current price and the $102.50 per share offer.
Market read
First‑time disclosure of earnings, FDA approvals, and merger terms makes this a high‑value trading story.
What to watch
Potential dilution from CVRs and the need for commercial milestones to unlock additional payments.
Background
Lantheus Holdings (LNTH) is a U.S. listed developer of radiopharmaceuticals. The company disclosed its Q3 2026 results, two FDA approvals, and a pending cash merger with Curium US Holdings.
Ticker impact
Lantheus reported Q3 2026 earnings, FDA approvals for TAUKLARIFY and BRAVNETSA, and announced a pending merger with Curium.
upside pressure as the market prices in the merger premium and FDA approvals
First disclosure of earnings and approvals plus a cash‑for‑stock merger at $102.50 per share creates immediate valuation upside.
Market effects
Positive signal for the nuclear imaging and radiopharma sector as FDA approvals may boost peers.
U.S. biotech and healthcare stocks could see modest gains.
Limited to U.S. and international investors tracking merger activity in the diagnostics space.
Counterpoint
Merger uncertainty and integration risk could weigh on price if regulatory clearance stalls.
Key entities
- companyLantheus Holdings
U.S. radiopharma company reporting earnings and FDA approvals.
- companyCurium US Holdings
Acquirer in the pending cash merger.
